These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 16678871)

  • 21. Treatment of New World cutaneous leishmaniasis with miltefosine.
    Soto J; Berman J
    Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S34-40. PubMed ID: 16930649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral miltefosine in the treatment of post-kala-azar dermal leishmaniasis.
    Ramesh V; Ansari NA; Jain RK; Salotra P
    Clin Exp Dermatol; 2008 Jan; 33(1):103-5. PubMed ID: 17979988
    [No Abstract]   [Full Text] [Related]  

  • 23. Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment.
    Calvopina M; Gomez EA; Sindermann H; Cooper PJ; Hashiguchi Y
    Am J Trop Med Hyg; 2006 Dec; 75(6):1074-7. PubMed ID: 17172368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Miltefosine effectively modulates the cytokine milieu in Indian post kala-azar dermal leishmaniasis.
    Mukhopadhyay D; Das NK; Roy S; Kundu S; Barbhuiya JN; Chatterjee M
    J Infect Dis; 2011 Nov; 204(9):1427-36. PubMed ID: 21933878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis.
    Jha TK; Sundar S; Thakur CP; Bachmann P; Karbwang J; Fischer C; Voss A; Berman J
    N Engl J Med; 1999 Dec; 341(24):1795-800. PubMed ID: 10588964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
    Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
    J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure.
    Dorlo TP; Rijal S; Ostyn B; de Vries PJ; Singh R; Bhattarai N; Uranw S; Dujardin JC; Boelaert M; Beijnen JH; Huitema AD
    J Infect Dis; 2014 Jul; 210(1):146-53. PubMed ID: 24443541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of visceral leishmaniasis: efficacy and limits of miltefosine].
    Gangneux JP; Marty P
    Sante; 2001; 11(4):257-8. PubMed ID: 11861203
    [No Abstract]   [Full Text] [Related]  

  • 29. Cutaneous infection with Leishmania infantum in an infant treated successfully with miltefosine.
    Neub A; Krahl D; Stich A; Amon U
    J Dtsch Dermatol Ges; 2008 Dec; 6(12):1061-4. PubMed ID: 18498377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo activity of perifosine against Leishmania amazonensis.
    Cabrera-Serra MG; Valladares B; Piñero JE
    Acta Trop; 2008 Oct; 108(1):20-5. PubMed ID: 18801328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.
    Sundar S; Rai M; Chakravarty J; Agarwal D; Agrawal N; Vaillant M; Olliaro P; Murray HW
    Clin Infect Dis; 2008 Oct; 47(8):1000-6. PubMed ID: 18781879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator-Picroliv.
    Shakya N; Sane SA; Vishwakarma P; Bajpai P; Gupta S
    Acta Trop; 2011 Aug; 119(2-3):188-93. PubMed ID: 21679679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.
    Dorlo TP; van Thiel PP; Huitema AD; Keizer RJ; de Vries HJ; Beijnen JH; de Vries PJ
    Antimicrob Agents Chemother; 2008 Aug; 52(8):2855-60. PubMed ID: 18519729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First case of typical Old World cutaneous leishmaniasis treated with miltefosine.
    Stojkovic M; Junghanss T; Krause E; Davidson RN
    Int J Dermatol; 2007 Apr; 46(4):385-7. PubMed ID: 17442078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis.
    Trinconi CT; Reimão JQ; Coelho AC; Uliana SR
    J Antimicrob Chemother; 2016 May; 71(5):1314-22. PubMed ID: 26851606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent.
    Soto J; Toledo J; Gutierrez P; Nicholls RS; Padilla J; Engel J; Fischer C; Voss A; Berman J
    Clin Infect Dis; 2001 Oct; 33(7):E57-61. PubMed ID: 11528586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ambisome plus miltefosine for Indian patients with kala-azar.
    Sundar S; Sinha PK; Verma DK; Kumar N; Alam S; Pandey K; Kumari P; Ravidas V; Chakravarty J; Verma N; Berman J; Ghalib H; Arana B
    Trans R Soc Trop Med Hyg; 2011 Feb; 105(2):115-7. PubMed ID: 21129762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Miltefosine: oral treatment of leishmaniasis.
    Soto J; Soto P
    Expert Rev Anti Infect Ther; 2006 Apr; 4(2):177-85. PubMed ID: 16597200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful miltefosine treatment of post-kala-azar dermal leishmaniasis occurring during antiretroviral therapy.
    Belay AD; Asafa Y; Mesure J; Davidson RN
    Ann Trop Med Parasitol; 2006 Apr; 100(3):223-7. PubMed ID: 16630379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use.
    Sundar S; Singh A; Rai M; Prajapati VK; Singh AK; Ostyn B; Boelaert M; Dujardin JC; Chakravarty J
    Clin Infect Dis; 2012 Aug; 55(4):543-50. PubMed ID: 22573856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.